ClinConnect ClinConnect Logo
Search / Trial NCT04003272

MDR - Comprehensive Reverse/Versa Dial Ti Glenosphere

Launched by ZIMMER BIOMET · Jun 26, 2019

Trial Information

Current as of May 29, 2025

Enrolling by invitation

Keywords

ClinConnect Summary

The objective of this retrospective/prospective consecutive series PMCF study is to collect data confirming safety, performance and clinical benefits of the Comprehensive Versa-Dial Reverse Ti Glenosphere when used for primary total shoulder arthroplasty, fractures and revision total shoulder arthroplasty (implants and instrumentation) at a 1,2,3,5,7 and 10-year follow-up\* to meet EU Medical Device and other regulatory requirements for post market surveillance. Because Comprehensive Reverse Ti Glenospheres have only been on the market since 2009, a prospective aspect to the study will be u...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Biomet Comprehensive Reverse Shoulder products are indicated for use in patients whose shoulder joint has a grossly deficient rotator cuff with severe arthropathy and/or previously failed shoulder joint replacement with a grossly deficient rotator cuff. The patient must be anatomically and structurally suited to receive the implants and a functional deltoid muscle is necessary.
  • The Comprehensive Reverse Shoulder is indicated for primary, fracture, or revision total shoulder replacement for the relief of pain and significant disability due to gross rotator cuff deficiency Glenoid components with Hydroxyapatite (HA) coating applied over the porous coating are indicated only for uncemented biological fixation applications. The Glenoid Baseplate components are intended for cementless application with the addition of screw fixation.
  • Interlok™ finish humeral stems are intended for cemented use and the MacroBond™ coated humeral stems are intended for press-fit or cemented applications. Humeral components with porous coated surface coating are indicated for either cemented or uncemented biological fixation applications.
  • \*\*\* For the specific components, Titanium (Ti) Glenospheres are intended for patients with Cobalt Alloy material sensitivity.
  • Exclusion Criteria:
  • Absolute contraindications include infection, sepsis, and osteomyelitis.
  • Relative contraindications include:
  • 1. Uncooperative patient or patient with neurologic disorders who is incapable or unwilling to follow directions.
  • 2. Osteoporosis.
  • 3. Metabolic disorders which may impair bone formation.
  • 4. Osteomalacia.
  • 5. Distant foci of infections which may spread to the implant site.
  • 6. Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram.
  • 7. Patient is a prisoner.
  • 8. Current alcohol or drug abuser.
  • 9. If female, patient is known to be pregnant or breastfeeding.
  • 10. Patient has a psychiatric illness or cognitive deficit that will not allow from proper informed consent.

About Zimmer Biomet

Zimmer Biomet is a leading global medical technology company specializing in the design, development, and manufacturing of innovative orthopedic and surgical products. With a commitment to enhancing patient outcomes, Zimmer Biomet focuses on advancing musculoskeletal health through a broad range of solutions, including joint reconstruction, surgical instrumentation, and dental implants. The company emphasizes research and development, conducting numerous clinical trials to evaluate the safety and effectiveness of its products, while fostering collaboration with healthcare professionals to address the evolving needs of patients and providers alike.

Locations

Buffalo, New York, United States

Louisville, Kentucky, United States

Patients applied

0 patients applied

Trial Officials

Erin Osborn

Study Director

Zimmer Biomet

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials